• Early White Matter Alterations Are Clinically Relevant in Huntington’s Patients, Study Shows
  • Experimental Huntington’s Treatment Improves Memory, Other Brain Functions in Mouse Study
  • Laquinimod Fails to Improve Motor Function but Reduces Brain Atrophy in Phase 2 Huntington’s Trial
  • PRIME Designation Should Help Promising Experimental Therapy Reach Huntington’s Patients Faster
  • Protein May Help Prevent Nerve Cell Death in Huntington’s Disease
  • Damage to Nuclear DNA Shown to Correlate with Huntington’s Duration, Patient’s Ability to Function
  • Phase 2a Trial Investigates BP Medicine SOM3355 as Treatment for Chorea
  • Genes Involved in Inflammation, Cellular Structure May Be Therapeutic Targets in Huntington’s
  • Retrotope’s RT001 Reduced Cognitive Defects in Mice with Huntington’s Disease, Study Shows
  • Improved Genetic Testing Protocols Should be Available for Huntington’s Disease, Study Contends
  • Skyhawk, Celgene Partner to Develop Small Molecule Treatments for Huntington’s, Other Neurological Diseases
  • Scotland’s Fife Launches Groundbreaking Local Care Frameworks for Huntington’s Disease